At Almirall, patients are at the centre of our purpose and our focus in medical dermatology.

Our primary focus is on patients, addressing both physical symptoms and emotional well-being through innovation and collaboration.

Collaborating with patient advocacy groups

In 2025, we continued supporting and collaborating with patient organisations globally and nationally.

IFPA

(International Federation of Psoriasis Associations)

Global Skin

(International Alliance of Dermatology Patient Organizations)

HS Connect

(International hidradenitis suppurativa patient community)

EFA

(European Federation of Allergy and Airways Diseases Patients’ Associations)

Disease awareness initiatives

We promote awareness of skin diseases through global campaigns, addressing both clinical and emotional impact on patients.

"The Deeper Truth" - World Psoriasis Day 2025

For World Psoriasis Day 2025, Almirall delivered an integrated awareness campaign built around “The Deeper Truth” narrative, aligned with IFPA’s theme “Stop the Domino Effect.” The campaign highlighted psoriasis as a systemic inflammatory disease and raised awareness of comorbidities and the broader burden beyond visible symptoms—supporting patient empowerment and encouraging informed conversations with healthcare professionals

"The Path to Feeling Lighter" - World Atopic Dermatitis Day 2025

On 2025 Global AD Day, Almirall launched a campaign featuring real patient testimonials and a unified omnichannel activation across key markets under the theme “Facing Atopic Eczema: The Path to Feeling Lighter,” developed closely with global patient associations to highlight the emotional burden of atopic dermatitis and the patients’ journey toward greater emotional freedom.

"Hats On for AK" - Actinic Keratosis World Day 2025:

For AK Global Day 2025, we launched the “Hats On Challenge”, a global initiative that united Europe and the US in raising awareness about actinic keratosis through fun, social driven sun protection actions. This campaign encouraged people to wear hats and spread the message of early detection and UV Prevention through social media venues.

Skin diseases can be chronic, relapsing and highly burdensome—often affecting patients’ well-being, relationships and daily life. In 2025, our continued focus remainedon areas where unmet need persists and where advances can deliver meaningful impact for patients and the medical community

We aim to transform patients’ lives by addressing both physical symptoms and overall well-being, supporting them in navigating the profound impact skin conditions have on their lives.

Addressing key diseases in dermatology

In 2025, Almirall reinforced its commitment to innovation in medical dermatology, investing 12.5% of net sales in R&D and advancing a high-potential pipeline, including three ongoing PoC/Phase II studies.

01 Inmune inflammatory diseases

Focus on atopic dermatitis and psoriasis with advanced therapies.

02 Non-melanoma skin cancer

In the area of non-melanoma skin cancer, we are advancing breakthrough treatments for conditions such as actinic keratosis.

03 Rare Diseases

In the rare disease space, we are dedicated to finding innovative solutions for over 1,000 rare dermatological diseases as more than 90% of these currently have no available treatment.

Our dermatology portfolio

Check it out

Key & strategic products of our portfolio

Find out more